Pnd139 - Impact of Prolonged-Release Fampridine on Fatigue Among People With Multiple Sclerosis in a Multi-Country Study

Abstract

OBJECTIVES: To characterize the functional, emotional and social impact of migraine in Portugal. METHODS: A worldwide, cross-sectional, online survey was conducted including migraine patients recruited via online panels and patient organizations from September 2017-February 2018. Study participants were adults reporting 4 or more monthly migraine days over the 3 months previous to survey with a pre-determined quota of 90% participants having received previous preventive migraine treatment. Results from the Portuguese sample are reported. RESULTS: A total of 143 migraine patients were included, 79.7% women and mean age of 37.3 years (SD 12.6; range 18-72). About 79.0% of participants mentioned feeling very or extremely limited in completing daily activities during the migraine attack. Indeed, 71.3% participants rely on support of family/friends to perform daily activities (average 11.8 hours in previous 3 months; SD 18.9; range 1-90). 39.2% of participants have often/always "no energy to complete daily living tasks or feel fatigued". Most common negative feelings perceived by participants were lack of others' understanding about their pain (53.9%), feeling helpless (42.7%) and depressed (40.0%). Nevertheless, 37.1% mentioned having learned to cope with the disease. Most patients (62.9%) claimed that migraine has changed their relationships with relatives/friends/partner and 81.1% of participants also mentioned that migraine has affected their social life and activities (48.3% cannot take part in usual activities/hobbies, 47.4% stopped social events). In the previous month, 80.4% of participants had to cancel plans due to migraine. As an overall consequence, 39.9% of patients mentioned being very/extremely fearful regarding next migraine attack. CONCLUSIONS: This study confirms that migraine is associated with functional impairment requiring support from others and a clear emotional and social impact in patients' lives.

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial

“…The results of the study showed that none of the medications was superior to placebo in improving MFIS; besides, unlike the placebo group, most of the patients in the intervention groups reported adverse events. 19 Although our study findings showed that both amantadine and dalfampridine improved MFIS, we did not make a comparison with a placebo group in this regard, which might affect the interpretation of the results.…”

“…There is some evidence that treatment with dalfampridine is effective for MS-related fatigue, 11 , 19 , 20 yet several studies have concluded that dalfampridine-extended release (ER) does not improve MS-related fatigue. 21 - 23 …”